國立虎尾科技大學 |

Development and Characterization of Novel Therapeutic Biologics to Enhance Immune Targeting of Clear Cell Renal Cell Carcinoma.

紀錄類型:	書目-語言資料,手稿 : Monograph/item
正題名/作者:	Development and Characterization of Novel Therapeutic Biologics to Enhance Immune Targeting of Clear Cell Renal Cell Carcinoma./
作者:	Zhang, Xiaoyu Sally.
面頁冊數:	1 online resource (82 pages)
附註:	Source: Masters Abstracts International, Volume: 58-01.
Contained By:	Masters Abstracts International58-01(E).
標題:	Biomedical engineering. -
電子資源:	click for full text (PQDT)
ISBN:	9780438187351

Development and Characterization of Novel Therapeutic Biologics to Enhance Immune Targeting of Clear Cell Renal Cell Carcinoma.
Zhang, Xiaoyu Sally.

Development and Characterization of Novel Therapeutic Biologics to Enhance Immune Targeting of Clear Cell Renal Cell Carcinoma. - 1 online resource (82 pages)

Source: Masters Abstracts International, Volume: 58-01.

Thesis (M.Sc.)--University of Toronto (Canada), 2018.

Includes bibliographical references

Metastatic clear cell renal cell carcinoma (ccRCC) remains incurable with low 5-year survival rates despite various targeted therapies and checkpoint immunotherapy. Owing to the tumours' immune sensitive nature and ubiquitous expression of a tumour-associated antigen carbonic anhydrase IX (CA9), this thesis exploits a novel immunotherapy strategy to target ccRCC using dual-specificity antibody T-cell engagers (DATEs). The CA9 DATEs were designed to engage human cytotoxic T cells against ccRCC cells by simultaneous binding to CD3 and CA9. My in vitro cytotoxicity co-culture results demonstrate that the CA9 DATEs potently redirected human T cells to lyse target cancer cells in an antigen-dependent manner across a panel of patient-derived ccRCC cell lines. In addition, T cell activation and cytotoxicity markers were up-regulated in concordance with cancer cell lysis. Collectively, my thesis provides proof-of-concept results with CA9 DATEs that can be further examined in pre-clinical models as a potential treatment strategy for metastatic ccRCC.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2018

Mode of access: World Wide Web

ISBN: 9780438187351Subjects--Topical Terms:

588770
Biomedical engineering.
Index Terms--Genre/Form:

554714
Electronic books.

Development and Characterization of Novel Therapeutic Biologics to Enhance Immune Targeting of Clear Cell Renal Cell Carcinoma.
LDR:02296ntm a2200325Ki 4500 001 918359
005 20181114145236.5
006 m o u
007 cr mn||||a|a||
008 190606s2018 xx obm 000 0 eng d
020 $a 9780438187351
035 $a (MiAaPQ)AAI10747183
035 $a (MiAaPQ)toronto:17282
035 $a AAI10747183
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Zhang, Xiaoyu Sally. $3 1192661
245 1 0 $a Development and Characterization of Novel Therapeutic Biologics to Enhance Immune Targeting of Clear Cell Renal Cell Carcinoma.
264 0 $c 2018
300 $a 1 online resource (82 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Masters Abstracts International, Volume: 58-01.
500 $a Adviser: Jason Moffat.
502 $a Thesis (M.Sc.)--University of Toronto (Canada), 2018.
504 $a Includes bibliographical references
520 $a Metastatic clear cell renal cell carcinoma (ccRCC) remains incurable with low 5-year survival rates despite various targeted therapies and checkpoint immunotherapy. Owing to the tumours' immune sensitive nature and ubiquitous expression of a tumour-associated antigen carbonic anhydrase IX (CA9), this thesis exploits a novel immunotherapy strategy to target ccRCC using dual-specificity antibody T-cell engagers (DATEs). The CA9 DATEs were designed to engage human cytotoxic T cells against ccRCC cells by simultaneous binding to CD3 and CA9. My in vitro cytotoxicity co-culture results demonstrate that the CA9 DATEs potently redirected human T cells to lyse target cancer cells in an antigen-dependent manner across a panel of patient-derived ccRCC cell lines. In addition, T cell activation and cytotoxicity markers were up-regulated in concordance with cancer cell lysis. Collectively, my thesis provides proof-of-concept results with CA9 DATEs that can be further examined in pre-clinical models as a potential treatment strategy for metastatic ccRCC.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2018
538 $a Mode of access: World Wide Web
650 4 $a Biomedical engineering. $3 588770
655 7 $a Electronic books. $2 local $3 554714
690 $a 0541
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a University of Toronto (Canada). $b Molecular and Medical Genetics. $3 1186169
773 0 $t Masters Abstracts International $g 58-01(E).
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10747183 $z click for full text (PQDT)